Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Investigating the ibrutinib resistance mechanism of L528W mutation on Bruton's tyrosine kinase via molecular dynamics simulations.

Journal of molecular graphics & modelling - 1 Jan 2024

Xu Biyu, Liang Luguang, Jiang Yirong, Zhao Zuguo

Abstract excerpt

Drug resistance to Bruton's Tyrosine Kinase (BTK) inhibitors presents a challenge in treating B-cell malignancies, and the mechanism behind drug resistance remains unclear. In this study, we focused on the BTK L528W mutation and investigated the underlying mechanisms of resistance to ibrutinib (including prototype and its active metabolite from, PCI-45227) using a combination of bioinformatics analysis, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Agammaglobulinaemia Tyrosine Kinase
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Dynamics Simulation

Share to Mutation

Share to Tyrosine Kinase Inhibitors

Source

Identifiers

PMID: 37716293
DOI: 10.1016/j.jmgm.2023.108623

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Investigating the ibrutinib resistance mechanism of L528W mutation on Bruton's tyrosine kinase via molecular dynamics simulations.PMID 37716293Read ↗

Microsecond simulations to investigate the structural mechanism of super-resistant double mutations in BTK to the covalent inhibitor ibrutinib in multiple leukemia.Semantic proximity Read ↗

Battling BTK mutants with noncovalent inhibitors that overcome Cys481 and Thr474 mutations in Waldenström macroglobulinemia therapy: structural mechanistic insights on the role of fenebrutinib.Semantic proximity Read ↗

Strategies to overcome resistance mutations of Bruton's tyrosine kinase inhibitor ibrutinib.Semantic proximity Read ↗

Computational insights into mutation-induced binding changes in Bruton's Tyrosine Kinase with non-covalent inhibitors.Semantic proximity Read ↗

Evaluating ibrutinib, pirtobrutinib, remibrutinib, rilzabrutinib, and zanubrutinib in 34 BTK-variants at 7 inhibitor resistance sitesSemantic proximity Read ↗

Rare deleterious mutations in Bruton's tyrosine kinase as biomarkers for ibrutinib-based therapy: an in silico insight.Semantic proximity Read ↗

How Does the L884P Mutation Confer Resistance to Type-II Inhibitors of JAK2 Kinase: A Comprehensive Molecular Modeling Study.Semantic proximity Read ↗

Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemiaSemantic proximity Read ↗

Virtual Screening and Identification of Non-covalent Reversible Small-molecule BTK Inhibitors from a Library of Known Bioactive CompoundsSemantic proximity Read ↗

Next-generation Bruton's Tyrosine Kinase (BTK) Inhibitors Potentially Targeting BTK C481S Mutation- Recent Developments and Perspectives.Semantic proximity Read ↗

Investigating mutations at the hotspot position of the ERBB2 and screening for the novel lead compound to treat breast cancer - a computational approach.Semantic proximity Read ↗

Differential impact of BTK active site inhibitors on the conformational state of full-length BTK.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.